May 02, 2022 / 06:30PM GMT
David Parkinson - ESSA Pharma Inc. - President, CEO & Director
Appreciate the opportunity to tell you where we are at. We will be giving a detailed update on clinical data to date at the end of June, so stay tuned for all of that. But in the meantime, I will take you through the story, take you where we are at, what we are trying to achieve, where we stand so far, and the likely path as we go forward into the future.
So as many of you know, ESSA was formed on biology and chemistry that came out of the University of British Columbia and the British Columbia Cancer Agency back in the early 2000s. And what is novel about what we are doing is we are working with a series of molecules that were developed by ESSA called Anitens. And what's unique about them is they shut down androgen-driven biology and do so from the N-terminal domain of the receptor.
Now all the antiandrogens which have -- and antiandrogen approaches which have been developed over the last six decades -- that's almost 70 years -- have involved the other end of the receptor, the ligand-binding domain. I will go in through
ESSA Pharma Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 02, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers